HC Wainwright Reaffirms Buy Rating for Valneva (NASDAQ:VALN)

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $17.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 151.67% from the company’s current price.

Separately, Guggenheim dropped their price target on Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, March 24th.

Valneva Trading Down 7.0 %

Shares of NASDAQ VALN traded down $0.51 during mid-day trading on Monday, reaching $6.76. The company had a trading volume of 15,343 shares, compared to its average volume of 26,206. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The business’s 50-day moving average is $6.63 and its 200-day moving average is $5.59. The stock has a market cap of $548.92 million, a price-to-earnings ratio of -51.96 and a beta of 1.93. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The business had revenue of $56.48 million during the quarter, compared to analysts’ expectations of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Equities analysts expect that Valneva will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN grew its holdings in Valneva SE (NASDAQ:VALN) by 14.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 246,766 shares of the company’s stock after buying an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned 0.30% of Valneva worth $1,079,000 as of its most recent SEC filing. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.